FDA telehealth GLP-1 warning letters: five marketing claims to question

01

What FDA announced in 2026

FDA's March 3 announcement said it issued 30 warning letters to telehealth companies for false or misleading claims about compounded GLP-1 products. The agency identified two broad patterns: implying that compounded products were the same as FDA-approved drugs and obscuring the source by presenting a telehealth company's brand in a way that implied it was the compounder.

FDA later published a consumer- and industry-facing summary of promotion it considers problematic. The page covers compounded GLP-1 drugs and other compounded drugs and points readers to the warning-letter database. The agency's examples make the enforcement theory easier to compare across individual letters.

The date and procedural posture matter. A warning letter states FDA's concerns and gives the recipient an opportunity to respond. It does not, by itself, establish liability in court. A current provider review should check later response, closeout, inspection, recall, and licensing records instead of freezing the company at the issue date.

02

Claim one: compounded means generic or the same

FDA says telehealth companies should not describe a compounded drug as a generic version of an approved drug or as the same as an FDA-approved product. An approved generic has an FDA application and must meet applicable approval standards. A compounded drug follows a different legal pathway and does not receive FDA premarket approval.

The distinction is not cured by naming an active ingredient. Product formulation, strength, excipients, container, labeling, handling, and oversight may differ. A provider can accurately identify an ingredient without implying that the finished compounded product is interchangeable with or reviewed like an approved drug.

Consumers should capture the exact wording and context. Same ingredient, generic, equivalent, identical, and just like can communicate a broader message than a narrow ingredient statement. Ask what evidence supports the comparison and which exact finished product was studied.

03

Claim two: the telehealth brand made the drug

FDA's Levity and Ready Med letters illustrate the source issue. The agency said pictured labels bearing the telehealth brand suggested that the company compounded the products when it did not. The legal analysis is specific to the displayed labeling and claims; consumers should read the letter rather than generalize from the company name alone.

A telehealth transaction can involve a consumer-facing platform, a medical group, an individual prescriber, a pharmacy, a laboratory, and a fulfillment or technology vendor. The provider should identify the responsible entities without using one brand to blur their roles.

Before paying, ask for the dispensing pharmacy's legal name and state, who makes the prescribing decision, and who handles medication complaints. After dispensing, match those answers to the patient label and pharmacy record. A platform logo is not a substitute for the compounder's identity.

04

Claims three and four: clinically proven and FDA-licensed

FDA warns against describing a compounded product as clinically proven to produce the same result as an approved drug. Evidence for an approved product cannot automatically establish the performance of a different compounded formulation. The advertiser needs support for the message consumers reasonably take from the claim.

FDA also says it does not approve or license pharmacies or outsourcing facilities. States license pharmacies, and an outsourcing facility can register with FDA under section 503B. Registration creates requirements and oversight; it is not a quality award, product approval, or facility endorsement.

Ask the provider to replace broad prestige language with checkable facts: state license, 503A or 503B pathway, registration date if relevant, exact pharmacy, product label, inspection context, and the study supporting the exact claim. If the response repeats the badge without evidence, the claim remains unresolved.

05

Claim five: compounding is allowed because of shortage

Shortage status can affect specific conditions under sections 503A and 503B, but it does not make a compounded drug approved or allow every copy claim. FDA's shortage-related GLP-1 updates show that product, date, facility type, and statutory condition all matter.

A provider should not use an old shortage screenshot as a permanent authorization. Check FDA's current shortage record and the dispensing date, then ask whether the provider relies on a patient-specific difference, a shortage condition, or another lawful basis. Do not infer the answer from availability or price.

The letters discussed here concern marketing. Whether a particular prescription or batch satisfies compounding conditions is a separate, fact-specific question. Consumers should avoid turning an advertising violation allegation into a medical conclusion about an individual patient.

06

A fair way to research a named company

Open the FDA letter and record the recipient, website reviewed, review date, issue date, products, quoted claims, and cited legal provisions. Then search the FDA database for a posted response or closeout letter. Check the current website for the claim, while recognizing that removal alone may not prove sustained correction.

Independently verify the current clinician and pharmacy. Review state board records, provider disclosures, recalls, FDA inspection information where relevant, and the label on the actual product. A warning letter does not replace these checks, and an absence of later enforcement is not a quality guarantee.

Use neutral language in notes: FDA alleged, the letter states, the company responded, or FDA posted a closeout. Do not say convicted, shut down, approved after correction, or cleared unless a source establishes that exact fact. Report a correction when a provider profile no longer matches the evidence.

• →Exact letter and recipient
• →Claims and products reviewed
• →Issue and website-review dates
• →Response or closeout status
• →Current clinician and pharmacy
• →Current label and dispensing pathway
• →Later inspection, recall, or enforcement records